CTCs as a Prognostic and Predictive Biomarker for Stage II/III Colon Cancer: A Companion Study to the PePiTA Trial

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5528-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Identification of a Sixteen-microRNA Signature as Prognostic Biomarker for Stage II and III Colon Cancer

Oncotarget
Oncology
2017English

Expression of Aquaporin-1 Is a Poor Prognostic Factor for Stage II and III Colon Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients With Stage II/III Colorectal Cancer

Cancers
Cancer ResearchOncology
2019English

Prognostic Impact of Mutation Profiling in Patients With Stage II and III Colon Cancer

Scientific Reports
Multidisciplinary
2016English

Prognostic Significance of Tumor Deposits in Patients With Stage III Colon Cancer: A Nomogram Study

Journal of Surgical Research
Surgery
2020English

P1.08-009 Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

RIPK3 Expression as a Potential Predictive and Prognostic Marker in Metastatic Colon Cancer

Clinical and Investigative Medicine
Medicine
2019English

Erratum: Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer (PePiTA): Protocol of a Prospective BGDO (Belgian Group for Digestive Oncology) Multicentric Study

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy